ABC | Volume 111, Nº3, Setembro 2018

Artigo Original Marino et al Adiponectina e VH-IVUS com as características da placa aterosclerótica Arq Bras Cardiol. 2018; 111(3):345-353 Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 21. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291(14):1730-7. 22. Schnabel R, Messow CM, Lubos E, Espinola-Klein C, Rupprecht HJ, Bickel C, et al. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study. Eur Heart J. 2008;29(5):649-57. 23. Forsblom C, Thomas MC, Moran J, Saraheimo M, Thorn L, Waden J, et al; FinnDiane Study Group. Serum adiponectin concentration is a positive predictor of all-cause and cardiovascular mortality in type 1 diabetes. J Intern Med. 2011;270(4):346-55. 24. Beatty AL, Zhang MH, Ku IA, Na B, Schiller NB, Whooley MA. Adiponectin is associatedwith increasedmortality and heart failure in patients with stable ischemic heart disease: data from theHeart and Soul Study. Atherosclerosis. 2012;220(2):587-92. 25. RathmannW,HerderC.Adiponectinandcardiovascularmortality:evidence for “reverse epidemiology”. HormMetab Res. 2007;39(1):1-2. 26. Shoji T, Koyama H, Fukumoto S, Maeno T, Yokoyama H, Shinohara K, et al. Platelet activation is associated with hypoadiponectinemia and carotid atherosclerosis. Atherosclerosis. 2006;188(1):190-5. 27. Bigalke B, Stellos K, Geisler T, Seizer P, Mozes V, Gawaz M. High plasma levels of adipocytokines are associated with platelet activation in patients with coronary artery disease. Platelets. 2010;21(1):11-9. 28. Van de Voorde J, Pauwels B, Boydens C, Decaluwe K. Adipocytokines in relation to cardiovascular disease. Metabolism. 2013;62(11):1513-21. 29. Ogasawara D, Shite J, Shinke T, Watanabe S, Otake H, Tanino Y, et al. Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus. Circ J. 2009;73(2):343-51. 30. Otake H, Shite J, Shinke T, Watanabe S, Tanino Y, Ogasawara D, et al. Relation between plasma adiponectin, high-sensitivity C-reactive protein, and coronary plaque components in patients with acute coronary syndrome. Am J Cardiol. 2008;101(1):1-7. 31. SawadaT,ShiteJ,ShinkeT,OtakeH,TaninoY,OgasawaraD,etal.Lowplasma adiponectin levels are associatedwith presence of thin-cap fibroatheroma in men with stable coronary artery disease. Int J Cardiol. 2010;142(3):250-6. 32. Shah AD, Kandula NR, Lin F, Allison MA, Carr J, Herrington D, et al. Less favorable body composition and adipokines in south asians compared to other U.S. ethnic groups: results from the MASALA and MESA studies. Int J Obes (Lond). 2016;40(4):639-45. 33. Yang WS, Chuang LM. Human genetics of adiponectin in the metabolic syndrome. J Mol Med (Berl). 2006;84(2):112-21. 34. Ohashi K, Ouchi N, Kihara S, Funahashi T, Nakamura T, Sumitsuji S, et al. Adiponectin I164Tmutation is associatedwith themetabolic syndrome and coronary artery disease. J Am Coll Cardiol. 2004;43(7):1195-200. 35. Garcia-Garcia HM, Costa MA, Serruys PW. Imaging of coronary atherosclerosis: intravascular ultrasound. Eur Heart J. 2010;31(20):2456-69. 36. Nicholls SJ, Hsu A, Wolski K, Hu B, BayturanO, Lavoie A, et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol. 2010;55(21):2399-407. 353